Open AccessChimeric Antigen Receptor T-Cell Therapy: An Overview of the Changing Face of Cancer Immunotherapy
Author(s) -
Pouya Safarzadeh Kozani,
Pooria Safarzadeh Kozani,
Fatemeh Rahbarizadeh
Publication year - 2021
Publication title -
trends in medical sciences
Language(s) - English
Resource type - Journals
ISSN - 2783-2090
DOI - 10.5812/tms.114656
Subject(s) - chimeric antigen receptor , immunotherapy , medicine , lymphoma , cancer immunotherapy , mantle cell lymphoma , cancer , cell therapy , t cell , cancer research , oncology , cytokine release syndrome , immunology , cell , immune system , biology , genetics
: Chimeric antigen receptor (CAR) T-cell therapy has emerged as the revolutionary cancer treatment method in recent years due to the heartwarming clinical outcomes in several types of hematologic malignancies. Since 2017, the US Food and Drug Administration has approved four CAR T-cell products, including tisagenlecleucel [for B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma (DLBCL)], axicabtagene ciloleucel (for DLBCL), brexucabtagene autoleucel (for mantle cell lymphoma), and lisocabtagene maraleucel (for DLBCL). The efficacy optimization and toxicity management methods of CAR T-cell therapy are among the most investigated fields of cancer immunotherapy. Furthermore, the favorable outcomes achieved by the aforementioned CAR T-cell products in hematologic malignancies have encouraged researchers to bring successful outcomes to solid tumor patients. This study aimed to highlight the outstanding characteristics and the manufacturing process of CAR T-cells and discuss the key lane leading to their clinically approved products.